Diminished brain synaptic plasma membrane Ca2+-ATPase activity in rats with streptozocin-induced diabetes

Association with reduced anesthetic requirements

Piotr Janicki, J. L. Horn, G. Singh, W. T. Franks, J. J. Franks

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Recent evidence suggests that chronic hyperglycemia may inhibit plasma membrane Ca2+-ATPase (PMCA) in cells from several tissues. Inhalational anesthetics (IA) can inhibit brain synaptic PMCA activity. We proposed that diabetic rats may manifest chronic inhibition of brain synaptic PMCA and thus provide a model for testing the hypothesis that synaptic PMCA plays a key role in IA pharmacodynamics. Ca2+ pumping activity of PMCA was measured in cerebral synaptic plasma membrane (SPM) vesicles prepared from rats with streptozocin (STZ)-induced diabetes and from control, normoglycemic rats. Dose requirements for halothane and xenon were estimated in treated and untreated rats. Brain PMCA activity in hyperglycemic rats was depressed by about 8.4%, compared to controls. In vitro glycation also caused a significant decrease in PMCA pumping activity. Halothane requirement for STZ-hyperglycemic rats was dramatically reduced to about 65% of control. Xenon requirement was also significantly reduced, to 88% of control. Correlation of IA dose with percent glycated hemoglobin for each rat revealed a strong association between reduced requirements for halothane or xenon and increased protein glycation. These results indicate that inhibition of brain synaptic PMCA in chronically hyperglycemic rats is associated with a significant reduction in IA requirement.

Original languageEnglish (US)
JournalLife Sciences
Volume55
Issue number18
DOIs
StatePublished - Jan 1 1994

Fingerprint

Synaptic Membranes
Experimental Diabetes Mellitus
Calcium-Transporting ATPases
Cell membranes
Streptozocin
Medical problems
Anesthetics
Rats
Brain
Cell Membrane
Xenon
Halothane
Rat control
Pharmacodynamics
Glycosylated Hemoglobin A
Hyperglycemia
Association reactions
Tissue

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{625a539ed9cb4174bf6fdb7e27718504,
title = "Diminished brain synaptic plasma membrane Ca2+-ATPase activity in rats with streptozocin-induced diabetes: Association with reduced anesthetic requirements",
abstract = "Recent evidence suggests that chronic hyperglycemia may inhibit plasma membrane Ca2+-ATPase (PMCA) in cells from several tissues. Inhalational anesthetics (IA) can inhibit brain synaptic PMCA activity. We proposed that diabetic rats may manifest chronic inhibition of brain synaptic PMCA and thus provide a model for testing the hypothesis that synaptic PMCA plays a key role in IA pharmacodynamics. Ca2+ pumping activity of PMCA was measured in cerebral synaptic plasma membrane (SPM) vesicles prepared from rats with streptozocin (STZ)-induced diabetes and from control, normoglycemic rats. Dose requirements for halothane and xenon were estimated in treated and untreated rats. Brain PMCA activity in hyperglycemic rats was depressed by about 8.4{\%}, compared to controls. In vitro glycation also caused a significant decrease in PMCA pumping activity. Halothane requirement for STZ-hyperglycemic rats was dramatically reduced to about 65{\%} of control. Xenon requirement was also significantly reduced, to 88{\%} of control. Correlation of IA dose with percent glycated hemoglobin for each rat revealed a strong association between reduced requirements for halothane or xenon and increased protein glycation. These results indicate that inhibition of brain synaptic PMCA in chronically hyperglycemic rats is associated with a significant reduction in IA requirement.",
author = "Piotr Janicki and Horn, {J. L.} and G. Singh and Franks, {W. T.} and Franks, {J. J.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/0024-3205(94)00761-6",
language = "English (US)",
volume = "55",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "18",

}

Diminished brain synaptic plasma membrane Ca2+-ATPase activity in rats with streptozocin-induced diabetes : Association with reduced anesthetic requirements. / Janicki, Piotr; Horn, J. L.; Singh, G.; Franks, W. T.; Franks, J. J.

In: Life Sciences, Vol. 55, No. 18, 01.01.1994.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diminished brain synaptic plasma membrane Ca2+-ATPase activity in rats with streptozocin-induced diabetes

T2 - Association with reduced anesthetic requirements

AU - Janicki, Piotr

AU - Horn, J. L.

AU - Singh, G.

AU - Franks, W. T.

AU - Franks, J. J.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Recent evidence suggests that chronic hyperglycemia may inhibit plasma membrane Ca2+-ATPase (PMCA) in cells from several tissues. Inhalational anesthetics (IA) can inhibit brain synaptic PMCA activity. We proposed that diabetic rats may manifest chronic inhibition of brain synaptic PMCA and thus provide a model for testing the hypothesis that synaptic PMCA plays a key role in IA pharmacodynamics. Ca2+ pumping activity of PMCA was measured in cerebral synaptic plasma membrane (SPM) vesicles prepared from rats with streptozocin (STZ)-induced diabetes and from control, normoglycemic rats. Dose requirements for halothane and xenon were estimated in treated and untreated rats. Brain PMCA activity in hyperglycemic rats was depressed by about 8.4%, compared to controls. In vitro glycation also caused a significant decrease in PMCA pumping activity. Halothane requirement for STZ-hyperglycemic rats was dramatically reduced to about 65% of control. Xenon requirement was also significantly reduced, to 88% of control. Correlation of IA dose with percent glycated hemoglobin for each rat revealed a strong association between reduced requirements for halothane or xenon and increased protein glycation. These results indicate that inhibition of brain synaptic PMCA in chronically hyperglycemic rats is associated with a significant reduction in IA requirement.

AB - Recent evidence suggests that chronic hyperglycemia may inhibit plasma membrane Ca2+-ATPase (PMCA) in cells from several tissues. Inhalational anesthetics (IA) can inhibit brain synaptic PMCA activity. We proposed that diabetic rats may manifest chronic inhibition of brain synaptic PMCA and thus provide a model for testing the hypothesis that synaptic PMCA plays a key role in IA pharmacodynamics. Ca2+ pumping activity of PMCA was measured in cerebral synaptic plasma membrane (SPM) vesicles prepared from rats with streptozocin (STZ)-induced diabetes and from control, normoglycemic rats. Dose requirements for halothane and xenon were estimated in treated and untreated rats. Brain PMCA activity in hyperglycemic rats was depressed by about 8.4%, compared to controls. In vitro glycation also caused a significant decrease in PMCA pumping activity. Halothane requirement for STZ-hyperglycemic rats was dramatically reduced to about 65% of control. Xenon requirement was also significantly reduced, to 88% of control. Correlation of IA dose with percent glycated hemoglobin for each rat revealed a strong association between reduced requirements for halothane or xenon and increased protein glycation. These results indicate that inhibition of brain synaptic PMCA in chronically hyperglycemic rats is associated with a significant reduction in IA requirement.

UR - http://www.scopus.com/inward/record.url?scp=0027947243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027947243&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(94)00761-6

DO - 10.1016/0024-3205(94)00761-6

M3 - Article

VL - 55

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 18

ER -